Glycogen synthase kinase-3β regulates anti-inflammatory property of fluoxetine

Hui Chen Su, Ching Ting Ma, Bu Chin Yu, Yu Chieh Chien, Cheng Chieh Tsai, Wei Ching Huang, Chiou Feng Lin, Yeu Hui Chuang, Kung Chia Young, Jieh Neng Wang, Chiung Wen Tsao

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

A selective serotonin reuptake inhibitor fluoxetine not only is widely used in the treatment of depression but also has an anti-inflammatory property. Glycogen synthase kinase-3beta (GSK-3β) is a vital factor in the inflammation process. How fluoxetine interferes with inflammation via a GSK-3β-dependent pathway remains unclear. The aim of this study is to investigate the effects of fluoxetine on lipopolysaccharide (LPS)-induced inflammation. Results showed that fluoxetine decreased mortality rate of the mice. It also inhibited LPS-induced release of nitric oxide (NO) and prostaglandin E2 (PGE2) in serum and RAW264.7 murine macrophages and expressions of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Upon LPS stimulation, fluoxetine caused a delay but increased in the phosphorylated levels of GSK-3β (ser9), whereas it did not affect LPS-induced activation of mitogen-activated protein kinase (MAPK) and generation of reactive oxygen species (ROS). Fluoxetine in combination with phosphatidylinositol 3-kinases/Akt inhibitors (LY294002 and Wortmannin) did not have a synergistic inhibition on LPS-induced NO release and PGE2 production. In addition, peroxisome proliferator-activated receptor γ (PPARγ) antagonist GW9622 showed no reverse effects of this inhibition of fluoxetine. GSK-3β knockdown blocked the inhibitory effects of fluoxetine on LPS-induced iNOS/NO release and COX-2/PGE2 production. These results indicated that GSK-3β regulated anti-inflammatory property of fluoxetine. However, Akt activation, ROS generation, and altered PPARγ activity were not involved in this inhibition of fluoxetine.

Original languageEnglish
Pages (from-to)150-156
Number of pages7
JournalInternational Immunopharmacology
Volume14
Issue number2
DOIs
Publication statusPublished - Oct 2012
Externally publishedYes

Fingerprint

Glycogen Synthase Kinase 3
Fluoxetine
Anti-Inflammatory Agents
Glycogen Synthase Kinases
Lipopolysaccharides
Dinoprostone
Nitric Oxide
Peroxisome Proliferator-Activated Receptors
Nitric Oxide Synthase Type II
Cyclooxygenase 2
Inflammation
Reactive Oxygen Species
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
Serotonin Uptake Inhibitors
Mitogen-Activated Protein Kinases
Phosphatidylinositol 3-Kinases
Macrophages

Keywords

  • COX-2/PGE2 production
  • Fluoxetine
  • GSK-3β
  • iNOS/NO release
  • Lipopolysaccharides

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology

Cite this

Su, H. C., Ma, C. T., Yu, B. C., Chien, Y. C., Tsai, C. C., Huang, W. C., ... Tsao, C. W. (2012). Glycogen synthase kinase-3β regulates anti-inflammatory property of fluoxetine. International Immunopharmacology, 14(2), 150-156. https://doi.org/10.1016/j.intimp.2012.06.015

Glycogen synthase kinase-3β regulates anti-inflammatory property of fluoxetine. / Su, Hui Chen; Ma, Ching Ting; Yu, Bu Chin; Chien, Yu Chieh; Tsai, Cheng Chieh; Huang, Wei Ching; Lin, Chiou Feng; Chuang, Yeu Hui; Young, Kung Chia; Wang, Jieh Neng; Tsao, Chiung Wen.

In: International Immunopharmacology, Vol. 14, No. 2, 10.2012, p. 150-156.

Research output: Contribution to journalArticle

Su, HC, Ma, CT, Yu, BC, Chien, YC, Tsai, CC, Huang, WC, Lin, CF, Chuang, YH, Young, KC, Wang, JN & Tsao, CW 2012, 'Glycogen synthase kinase-3β regulates anti-inflammatory property of fluoxetine', International Immunopharmacology, vol. 14, no. 2, pp. 150-156. https://doi.org/10.1016/j.intimp.2012.06.015
Su, Hui Chen ; Ma, Ching Ting ; Yu, Bu Chin ; Chien, Yu Chieh ; Tsai, Cheng Chieh ; Huang, Wei Ching ; Lin, Chiou Feng ; Chuang, Yeu Hui ; Young, Kung Chia ; Wang, Jieh Neng ; Tsao, Chiung Wen. / Glycogen synthase kinase-3β regulates anti-inflammatory property of fluoxetine. In: International Immunopharmacology. 2012 ; Vol. 14, No. 2. pp. 150-156.
@article{242fbeab3ee040e8be52e66857de44c1,
title = "Glycogen synthase kinase-3β regulates anti-inflammatory property of fluoxetine",
abstract = "A selective serotonin reuptake inhibitor fluoxetine not only is widely used in the treatment of depression but also has an anti-inflammatory property. Glycogen synthase kinase-3beta (GSK-3β) is a vital factor in the inflammation process. How fluoxetine interferes with inflammation via a GSK-3β-dependent pathway remains unclear. The aim of this study is to investigate the effects of fluoxetine on lipopolysaccharide (LPS)-induced inflammation. Results showed that fluoxetine decreased mortality rate of the mice. It also inhibited LPS-induced release of nitric oxide (NO) and prostaglandin E2 (PGE2) in serum and RAW264.7 murine macrophages and expressions of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Upon LPS stimulation, fluoxetine caused a delay but increased in the phosphorylated levels of GSK-3β (ser9), whereas it did not affect LPS-induced activation of mitogen-activated protein kinase (MAPK) and generation of reactive oxygen species (ROS). Fluoxetine in combination with phosphatidylinositol 3-kinases/Akt inhibitors (LY294002 and Wortmannin) did not have a synergistic inhibition on LPS-induced NO release and PGE2 production. In addition, peroxisome proliferator-activated receptor γ (PPARγ) antagonist GW9622 showed no reverse effects of this inhibition of fluoxetine. GSK-3β knockdown blocked the inhibitory effects of fluoxetine on LPS-induced iNOS/NO release and COX-2/PGE2 production. These results indicated that GSK-3β regulated anti-inflammatory property of fluoxetine. However, Akt activation, ROS generation, and altered PPARγ activity were not involved in this inhibition of fluoxetine.",
keywords = "COX-2/PGE2 production, Fluoxetine, GSK-3β, iNOS/NO release, Lipopolysaccharides",
author = "Su, {Hui Chen} and Ma, {Ching Ting} and Yu, {Bu Chin} and Chien, {Yu Chieh} and Tsai, {Cheng Chieh} and Huang, {Wei Ching} and Lin, {Chiou Feng} and Chuang, {Yeu Hui} and Young, {Kung Chia} and Wang, {Jieh Neng} and Tsao, {Chiung Wen}",
year = "2012",
month = "10",
doi = "10.1016/j.intimp.2012.06.015",
language = "English",
volume = "14",
pages = "150--156",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Glycogen synthase kinase-3β regulates anti-inflammatory property of fluoxetine

AU - Su, Hui Chen

AU - Ma, Ching Ting

AU - Yu, Bu Chin

AU - Chien, Yu Chieh

AU - Tsai, Cheng Chieh

AU - Huang, Wei Ching

AU - Lin, Chiou Feng

AU - Chuang, Yeu Hui

AU - Young, Kung Chia

AU - Wang, Jieh Neng

AU - Tsao, Chiung Wen

PY - 2012/10

Y1 - 2012/10

N2 - A selective serotonin reuptake inhibitor fluoxetine not only is widely used in the treatment of depression but also has an anti-inflammatory property. Glycogen synthase kinase-3beta (GSK-3β) is a vital factor in the inflammation process. How fluoxetine interferes with inflammation via a GSK-3β-dependent pathway remains unclear. The aim of this study is to investigate the effects of fluoxetine on lipopolysaccharide (LPS)-induced inflammation. Results showed that fluoxetine decreased mortality rate of the mice. It also inhibited LPS-induced release of nitric oxide (NO) and prostaglandin E2 (PGE2) in serum and RAW264.7 murine macrophages and expressions of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Upon LPS stimulation, fluoxetine caused a delay but increased in the phosphorylated levels of GSK-3β (ser9), whereas it did not affect LPS-induced activation of mitogen-activated protein kinase (MAPK) and generation of reactive oxygen species (ROS). Fluoxetine in combination with phosphatidylinositol 3-kinases/Akt inhibitors (LY294002 and Wortmannin) did not have a synergistic inhibition on LPS-induced NO release and PGE2 production. In addition, peroxisome proliferator-activated receptor γ (PPARγ) antagonist GW9622 showed no reverse effects of this inhibition of fluoxetine. GSK-3β knockdown blocked the inhibitory effects of fluoxetine on LPS-induced iNOS/NO release and COX-2/PGE2 production. These results indicated that GSK-3β regulated anti-inflammatory property of fluoxetine. However, Akt activation, ROS generation, and altered PPARγ activity were not involved in this inhibition of fluoxetine.

AB - A selective serotonin reuptake inhibitor fluoxetine not only is widely used in the treatment of depression but also has an anti-inflammatory property. Glycogen synthase kinase-3beta (GSK-3β) is a vital factor in the inflammation process. How fluoxetine interferes with inflammation via a GSK-3β-dependent pathway remains unclear. The aim of this study is to investigate the effects of fluoxetine on lipopolysaccharide (LPS)-induced inflammation. Results showed that fluoxetine decreased mortality rate of the mice. It also inhibited LPS-induced release of nitric oxide (NO) and prostaglandin E2 (PGE2) in serum and RAW264.7 murine macrophages and expressions of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Upon LPS stimulation, fluoxetine caused a delay but increased in the phosphorylated levels of GSK-3β (ser9), whereas it did not affect LPS-induced activation of mitogen-activated protein kinase (MAPK) and generation of reactive oxygen species (ROS). Fluoxetine in combination with phosphatidylinositol 3-kinases/Akt inhibitors (LY294002 and Wortmannin) did not have a synergistic inhibition on LPS-induced NO release and PGE2 production. In addition, peroxisome proliferator-activated receptor γ (PPARγ) antagonist GW9622 showed no reverse effects of this inhibition of fluoxetine. GSK-3β knockdown blocked the inhibitory effects of fluoxetine on LPS-induced iNOS/NO release and COX-2/PGE2 production. These results indicated that GSK-3β regulated anti-inflammatory property of fluoxetine. However, Akt activation, ROS generation, and altered PPARγ activity were not involved in this inhibition of fluoxetine.

KW - COX-2/PGE2 production

KW - Fluoxetine

KW - GSK-3β

KW - iNOS/NO release

KW - Lipopolysaccharides

UR - http://www.scopus.com/inward/record.url?scp=84864124950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864124950&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2012.06.015

DO - 10.1016/j.intimp.2012.06.015

M3 - Article

C2 - 22749848

AN - SCOPUS:84864124950

VL - 14

SP - 150

EP - 156

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 2

ER -